Etrasimod is a Small Molecule owned by Pfizer, and is involved in 26 clinical trials, of which 17 were completed, 8 are ongoing, and 1 is planned.
Etrasimod (APD-334) acts as S1P1, S1P4 and S1P5 receptor agonist. Sphingosine 1-phosphate (S1P) is an important regulator of many different immune functions including lymphocyte circulation, antigen presentation, and T cell development. S1P receptors couple to different heterotrimeric G proteins and elicit cellular signaling events by activating the small GTPases Rac and Rho and protein kinases Akt, ERK, and JNK and by inducing cellular calcium flux and inhibiting cAMP accumulation. The drug candidate by agonizing S1P receptors alleviates the disease condition.
The revenue for Etrasimod is expected to reach a total of $5.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Etrasimod NPV Report.
Etrasimod (APD-334) is under development for the treatment of moderately to severely active ulcerative colitis, Crohn's disease, atopic dermatitis, alopecia areta and Eosinophilic Esophagitis (EOE). The drug candidate is a next-generation small molecule and is administered through oral route. It acts by targeting S1P1, S1P4 and S1P5 receptors. It is developed based on GPCR-based drug discovery technology platform. It was also under development for autoimmune diseases such as multiple sclerosis, psoriasis, rheumatoid arthritis and dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease. It was also under development for pyoderma gangrenosum and primary biliary cirrhosis (cholangitis).
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.
Quick View – Etrasimod
|Highest Development Stage|